Showing 971-980 of 18562 results for "".
The FDA Expands Indication for Baloxavir Marboxil to Include Post-Exposure Influenza Prevention
https://reachmd.com/programs/the-drug-report/the-fda-expands-indication-for-baloxavir-marboxil-to-include-post-exposure-influenza-prevention/12043/Previously used for acute uncomplicated influenza, baloxavir marboxil has been approved by the FDA for post-exposure influenza prevention.The Impact of ESHRE 2017 on Japanese Fertility Practice
https://reachmd.com/programs/global-womens-health-academy/impact-eshre-2017-japanese-fertility-practice/9787/This activity includes summaries and impacts of ESHRE 2017 from thought leaders, pertaining to practicing Japanese fertility specialists.Collaborative Care for CRSwNP Expert and Patient Insights
https://reachmd.com/programs/cme/collaborative-care-for-crswnp-expert-and-patient-insights/36695/Chronic rhinosinusitis with nasal polyps (CRSwNP) presents a large burden on more than 3 million patients with the conditions — especially when intertwined with asthma and allergy. Join our discussion between patients with CRSwNP and leading experts in ENT, allergy, and pulmonary medicine as they:Decoding Itch in CKD: From CKD-aP Suspicion to Solution
https://reachmd.com/programs/cme/decoding-itch-in-ckd-from-ckd-ap-suspicion-to-solution/26640/Review best practices in CKD-aP diagnosis, treatment and management, including the role of multidisciplinary care and shared decision-making to improve quality of life.Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
https://reachmd.com/programs/cme/clinical-implications-of-emerging-data-on-b7-h3directed-adcs-in-the-future-of-es-sclc/39979/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
https://reachmd.com/programs/project-oncology/her2-testing-the-evolving-role-of-immunohistochemistry-ihc/29129/Best Practices and Interpretation of Results in Lung and Ovarian CancerThe New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
https://reachmd.com/programs/cme/the-new-era-of-ras-targeting-mechanisms-evidence-and-clinical-integration-of-on-state-inhibitors/39770/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.IBD Immunopathogenesis: Do You Know What You're Blocking?
https://reachmd.com/programs/cme/ibd-immunopathogenesis-do-you-know-what-youre-blocking/51482/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.Evaluating Alemtuzumab in Adult ALL: Insights from a Phase 1/2 Clinical Trial
https://reachmd.com/programs/project-oncology/evaluating-alemtuzumab-in-adult-all-insights-from-a-phase-12-clinical-trial/32993/Alemtuzumab may have potential as an adult acute lymphoblastic leukemia treatment. Dive deeper into its safety, efficacy, and implications for care.Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
https://reachmd.com/programs/acc-action-center/long-term-improvements-in-daily-steps-with-gamification-and-financial-incentives-in-patients-at-risk-for-cv-events/24347/ACC.24 - Alexander Fanaroff shares the results of the BE ACTIVE trial, which investigated the long-term efficacy of gamification, financial incentives, or a combination of both approaches for increasing physical activity in patients at risk for cardiovascular events.